Ascendis Pharma A/S
TransCon CNP
pediatric achondroplasia
Resolved
129days ago
FDA decision · Feb 28, 2026
What's at stake
The FDA's approval decision on TransCon CNP for pediatric achondroplasia is due Feb 28, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 13h ago
“In the U.S., PDUFA goal date of February 28, 2026 for pediatric achondroplasia.”